Eritoran for COVID-19: real-time analysis

Download Image

Post

c19early.org

Eritoran for COVID-19

1 study with 96 patients

Serious outcome risk

Eritoran

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Eritoran studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−26%

Mortality (1)−26%

RCTs (1)−26%

Late (1)−26%

00.511.5+

← Eritoran
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Eritoran is a synthetic glycolipid anti-inflammatory/immunomodulatory drug - a lipid A analogue that binds MD-2 and blocks activation of the Toll-like receptor 4 (TLR4) pathway, proposed for COVID-19 to reduce excessive host inflammatory signaling. Recent:

Saito.


Sep 15	Saito et al., CMI Communications, doi:10.1016/j.cmicom.2026.105223	Eritoran and Apremilast in hospitalized patients with COVID-19: the REMAP-CAP Immune Modulation-2 Domain
Sep 15	26% higher mortality (p=0.69), 7% lower progression (p=1), and 1% improvement (p=0.99). RCT 104 hospitalized patients with COVID-19 showing no significant difference in organ support-free days or mortality with eritoran (TLR4 antagonist) vs. placebo.